Get the Daily Brief
Latest Biotech News
Retrons join the gene‑editing toolkit: metagenomic discovery to engineering
Researchers screened metagenomic datasets and identified retron reverse transcriptases that generate intracellular single‑stranded DNA, then validated and engineered those elements as programmable...
Live embryo imaging upends assumptions about preimplantation aneuploidy
Teams using light‑sheet live imaging tracked late‑stage human preimplantation embryos and found de novo mitotic chromosome segregation errors in cells destined for the trophectoderm, raising...
Lilly buys Adverum — scoops up cash‑strapped gene therapy leader
Eli Lilly agreed to acquire Adverum in a deal that transfers ownership of the biotech’s phase‑3 AAV gene therapy candidate for wet age‑related macular degeneration (ixo‑vec) to the Indianapolis...
FDA returns Blenrep: limited approval with Velcade combo
The U.S. Food and Drug Administration cleared GSK’s antibody‑drug conjugate Blenrep for use in multiple myeloma in a restricted setting, approving the drug only in combination with a Velcade‑based...
Moderna’s CMV vaccine fails Phase 3 — program largely halted
Moderna reported that its mRNA cytomegalovirus vaccine missed primary efficacy endpoints in a pivotal Phase III trial and will stop most development of the candidate. The failure removes what had...
AI finds antibiotics: deep learning surfaces novel antibacterial scaffolds
Two complementary reports in Nature Biotechnology describe how deep‑learning models trained on high‑throughput screening and phenotypic data accelerated discovery of novel antibacterial compounds....
LNP blueprints emerge — biophysics maps nanoparticle diversity
Teams from UPenn, Brookhaven and commercial partners published biophysical analyses that resolve structural heterogeneity across lipid nanoparticle (LNP) formulations used for RNA delivery. The...
Live embryo imaging flags mitotic errors — PGT‑A under scrutiny
Researchers using optimized long‑term light‑sheet imaging of human preimplantation embryos observed de novo mitotic chromosome segregation errors at blastocyst stages, findings reported in Nature...
Retrons repurposed — new retron‑based editors promise large DNA fixes
A Nature Biotechnology report and accompanying analyses describe the discovery and engineering of bacterial retrons for precise genome editing. Authors used metagenomic screening to identify...
Biogen bets on C5aR1: $70M upfront for Vanqua’s preclinical asset
Biogen acquired exclusive global rights to Vanqua Bio’s preclinical C5aR1 antagonist (VQ‑201), paying $70 million upfront with additional contingent milestones. The deal reflects Biogen’s renewed...
Ventyx NLRP3 pill slashes inflammation markers — markets rally
Ventyx Biosciences reported Phase II data showing its oral NLRP3 inhibitor VTX‑3232 produced rapid, large reductions in inflammatory biomarkers and liver inflammation measures in patients with...
Regeneron shelves 2seventy CAR‑T — early lymphoma candidate discontinued
Regeneron confirmed it has halted development of a CAR‑T candidate (bbT369) acquired from 2seventy bio and will not proceed to a planned Phase II study. The company described the decision as...
Takeda-Innovent deal: $11.4bn package, $1.2bn up front
Takeda agreed to a multi-asset oncology partnership with China’s Innovent Biologics that includes $1.2 billion in up-front consideration and up to $10.2 billion in milestone payments. The...
Moderna halts CMV shot: Phase III failure forces pullback
Moderna announced that its cytomegalovirus (CMV) mRNA vaccine mRNA‑1647 failed to meet the primary efficacy endpoint in a pivotal Phase III trial and is halting most development of the program....
Regeneron shelves 2seventy CAR‑T bbT369: early program stopped
Regeneron confirmed it has discontinued development of bbT369, a CAR‑T candidate acquired from 2seventy bio, and will not advance the asset into Phase II. The firm described the decision as a...
Ventyx’s NLRP3 inhibitor: single‑arm signal shakes up cardio inflammation space
Ventyx Biosciences reported Phase II results showing its oral NLRP3 inhibitor VTX‑3232 produced rapid reductions in inflammatory biomarkers and surrogate measures of cardiovascular risk, including...
Inhibrx posts phase II win in rare bone cancer — FDA path planned
Inhibrx reported a positive Phase II readout for ozekibart in a rare bone cancer with no approved therapies, prompting the company to plan an FDA submission in the second half of 2026. The...
FDA clears Blenrep comeback — approval split by regimen
The FDA approved GSK’s antibody‑drug conjugate Blenrep for a restricted multiple myeloma indication after a three‑year market withdrawal, authorizing its use in combination with a Velcade‑based...
LNP blueprints: biophysics study links shape to delivery
Two complementary reports mapped lipid nanoparticle (LNP) architectures and linked particle morphology to delivery performance, providing actionable guidance for RNA‑therapeutic formulation....
Retrons retooled: new genome‑editing tool boosts precise insertions
A Nature Biotechnology study and accompanying reports described the discovery and engineering of bacterial retrons as a scalable route to produce multicopy single‑stranded DNA templates inside...